Greater than 50 Percent Reduction in Patients Classified as Low Risk for Lung Cancer SAN FRANCISCO --(BUSINESS WIRE)-- Correcting quote attribution in the third paragraph of release issued Nov. 1, 2017 . The corrected release reads: VERACYTE ANNOUNCES PRESENTATION OF NEW CLINICAL UTILITY DATA AT
SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2016 /PRNewswire/ -- Veracyte, Inc. ( NASDAQ : VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies
SOUTH SAN FRANCISCO, Calif. , May 3, 2016 /PRNewswire/ -- Veracyte, Inc. ( NASDAQ : VCYT) today announced that data from multiple studies supporting the company's genomic tests to resolve ambiguity in pulmonary disease diagnosis will be presented at the American Thoracic Society (ATS) 2016
SOUTH SAN FRANCISCO, Calif. , May 11, 2015 /PRNewswire/ -- Veracyte, Inc . (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, announced that company President and CEO Bonnie H. Anderson has been selected to Fast Company 's " 100 Most Creative People in
Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis Cambridge, Mass. and South San Francisco, Calif. --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY ), and Veracyte, Inc., a molecular diagnostics company
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients Cambridge, Mass. and South San Francisco, Calif. --- January 20, 2012 --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world’s leading biotechnology companies,
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.